Ginkgo Bioworks Holdings, Inc. $DNA Shares Bought by PDT Partners LLC

Key Points

• PDT Partners LLC increased its holdings in Ginkgo Bioworks by 104.0%, acquiring an additional 196,350 shares to own a total of 385,153 shares, valued at approximately $2.2 million.
• Ginkgo Bioworks' stock has experienced a 13.1% decline, trading at $11.02, with a 12-month low of $5.00 and high of $16.85.
• Despite a negative earnings report with a loss of ($1.10) per share, Ginkgo Bioworks exceeded revenue expectations with $49.6 million for the quarter.

PDT Partners LLC grew its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 104.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 385,153 shares of the company's stock after buying an additional 196,350 shares during the period. PDT Partners LLC owned 0.66% of Ginkgo Bioworks worth $2,195,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Bank of America Corp DE increased its position in Ginkgo Bioworks by 780.6% during the fourth quarter. Bank of America Corp DE now owns 3,764,455 shares of the company's stock valued at $36,967,000 after acquiring an additional 3,336,964 shares during the last quarter. Erste Asset Management GmbH increased its position in Ginkgo Bioworks by 123.2% during the first quarter. Erste Asset Management GmbH now owns 1,650,000 shares of the company's stock valued at $9,405,000 after acquiring an additional 910,668 shares during the last quarter. Forbes J M & Co. LLP increased its position in Ginkgo Bioworks by 56.0% during the first quarter. Forbes J M & Co. LLP now owns 1,094,564 shares of the company's stock valued at $6,239,000 after acquiring an additional 392,832 shares during the last quarter. Millennium Management LLC increased its position in Ginkgo Bioworks by 357.4% during the fourth quarter. Millennium Management LLC now owns 670,065 shares of the company's stock valued at $6,580,000 after acquiring an additional 523,571 shares during the last quarter. Finally, Cubist Systematic Strategies LLC increased its position in Ginkgo Bioworks by 188.9% during the first quarter. Cubist Systematic Strategies LLC now owns 439,259 shares of the company's stock valued at $2,504,000 after acquiring an additional 287,221 shares during the last quarter. 78.63% of the stock is currently owned by institutional investors.

Ginkgo Bioworks Price Performance

NYSE DNA traded down $0.57 during mid-day trading on Friday, hitting $11.12. The stock had a trading volume of 2,090,344 shares, compared to its average volume of 1,591,243. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $5.00 and a twelve month high of $16.85. The stock has a market capitalization of $658.01 million, a price-to-earnings ratio of -1.90 and a beta of 1.50. The firm's 50 day moving average is $12.16 and its 200 day moving average is $9.26.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.44) by $0.34. The business had revenue of $49.60 million for the quarter, compared to analyst estimates of $41.60 million. Ginkgo Bioworks had a negative return on equity of 43.25% and a negative net margin of 136.56%. Ginkgo Bioworks has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

DNA has been the topic of a number of analyst reports. BTIG Research boosted their price objective on shares of Ginkgo Bioworks from $6.00 to $9.00 and gave the company a "sell" rating in a research report on Monday, August 25th. Wall Street Zen upgraded shares of Ginkgo Bioworks from a "sell" rating to a "hold" rating in a report on Saturday, August 30th. Finally, Cowen restated a "buy" rating on shares of Ginkgo Bioworks in a report on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $9.50.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.